Physician profile
Huma Shakil
NPI 1790857688
$6,074.68
in general payments reported to CMS, 2019-2025
40 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $529 · 2021: $868 · 2022: $984 · 2023: $696 · 2024: $857 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,709 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,709.17 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $618.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $612.06 | 2021-2025 | Ubrelvy, Synthroid, Vraylar |
| Janssen Pharmaceuticals, INC | $584.47 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $517.80 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $383.85 | 2019-2025 | |
| Lilly USA, LLC | $379.35 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $343.54 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $266.67 | 2019-2025 | Otezla, Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $262.41 | 2019-2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.90 | 2019-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $178.73 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $176.11 | 2019-2025 | |
| Amarin Pharma, INC. | $150.26 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $135.63 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $120.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huma Shakil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.